Abbott Laboratories (N:ABT)
Business Focus: Medical Equipment, Supplies & Distribution
Apr 23, 2024 03:45 pm ET
It’s Draft Day: Damar Hamlin Helps Build the Abbott HeartMates Team
NORTHAMPTON, MA / ACCESSWIRE / April 23, 2024 / AbbottEleven new HeartMates with 11 inspiring stories recognized at Abbott HeartMates Draft Day event in NYC.
Apr 17, 2024 07:30 am ET
Abbott Reports First-Quarter 2024 Results and Raises Midpoint of Full-Year Guidance Ranges
Sales of $10.0 billion driven by strong underlying base business performance Reported sales increased 2.2 percent, which includes the impact from the anticipated decline in COVID-19 testing-related sales versus prior yearOrganic sales growth for underlying base business of 10.8 percent, which represents the fifth consecutive quarter of double-digit growth1 ABBOTT PARK, Ill., April 17, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2024.
Apr 02, 2024 09:00 am ET
Abbott Receives FDA Approval for TriClip™, First-of-Its-Kind Device to Repair Leaky Tricuspid Heart Valve
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgeryMore than 1.6 million people in the U.S. are affected by tricuspid regurgitation,1 which can severely impact quality of lifeData from the TRILUMINATE™ Pivotal trial demonstrated that patients who received TriClip experienced a marked improvement in the severity of their symptoms and quality of life, with benefits sustained at one yearABBOTT PARK, Ill., April 2, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and
Apr 01, 2024 09:00 am ET
Abbott Receives FDA Clearance for Whole Blood Rapid Test to Help with Assessment of Concussion at the Patient's Bedside
The test, run on Abbott's portable i-STAT® Alinity® instrument, uses whole blood to help evaluate patients with a suspected mild traumatic brain injury (mTBI), or concussionThe test produces lab-quality results in 15 minutesClinicians are now able to get a result at the patient's bedside, making the test accessible at urgent care clinics and other healthcare settings outside the hospital emergency roomThe test can be used to help evaluate patients up to 24 hours after injuryABBOTT PARK, Ill., April 1, 2024 /PRNewswire/ -- Abbott's i-STAT TBI cartridge has received clearance from the U.S. Foo
Mar 27, 2024 04:30 pm ET
Abbott Hosts Conference Call for First-Quarter Earnings
ABBOTT PARK, Ill., March 27, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its first-quarter 2024 financial results on Wednesday, April 17, before the market opens.
Mar 19, 2024 08:00 am ET
Canadian First - Abbott Advances Chronic Pain Management with the World's Smallest Implanted, Rechargeable Spinal Cord Stimulation System
Abbott's Eterna™ SCS system to treat chronic pain was used for the first time in Canada at Hôpital de l'Enfant-Jésus hospital in Quebec City.The device is the smallest implantable rechargeable spinal cord stimulator (SCS)*3 and provides the ability to deliver therapy while only requiring wireless recharging five times per year,1,2 meaning less frequent charging for the chronic pain patients being treated.§4MONTRÉAL, March 19, 2024 /CNW/ -- Abbott (NYSE: ABT) today announced that the company's Eterna™ SCS system – the smallest implantable, rechargeable spinal cord stimulator (SCS) for the tre
Mar 15, 2024 08:30 am ET
Diabetes and Heart Disease: How to Manage Your Risk
NORTHAMPTON, MA / ACCESSWIRE / March 15, 2024 / Abbott
Mar 11, 2024 10:10 am ET
Feb 20, 2024 03:00 am ET
Medical Technology Stocks to Keep On The Radar
The healthcare
technology industry is one that offers investors a plethora of
opportunities. With global healthcare spending soaring to
approximately $8.3 trillion and nearly half of that amount allocated
in the U.S. alone, the sector presents intriguing growth prospects. As
the healthcare industry outpaces the overall global economy in growth,
investors find themselves on the cusp of a promising market.
Feb 16, 2024 09:19 am ET
Abbott Declares 401st Consecutive Quarterly Dividend
ABBOTT PARK, Ill., Feb. 16, 2024 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 55 cents per share.
Feb 13, 2024 05:47 pm ET
FDA Advisory Committee Votes in Favor of Abbott's First-of-Its-Kind TriClip™ System to Treat People With a Leaky Tricuspid Heart Valve
Panel of independent experts reviewed data from the TRILUMINATE™ pivotal trial demonstrating safety, effectiveness and quality-of-life benefits of the TriClip systemAn investigational device in the U.S., TriClip is approved in more than 50 countries and has treated more than 10,000 people with tricuspid regurgitation worldwideABBOTT PARK, Ill., Feb. 13, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the Circulatory System Devices Panel of the Medical Devices Advisory Committee for the U.S. Food and Drug Administration (FDA) confirmed 13 to 1, with 0 abstention that the benefits
Feb 08, 2024 08:30 am ET
New Study Shows Mixed Reality Technology for Blood Donation From Abbott and Blood Centers of America Helps Ease Stress, Encourages People To Donate Again
ABBOTT PARK, IL / ACCESSWIRE / February 8, 2024 / Abbott
Feb 06, 2024 08:30 am ET
Decade of Impact: Transforming Care in Tanzania
Ten years ago, pioneers helped introduce emergency medicine. Now, they care for more than 1.2 million people.
Feb 05, 2024 08:25 am ET
Abbott Launches New PROTALITY(TM) Brand To Support Adults on Their Weight Loss Journey
ABBOTT PARK, IL / ACCESSWIRE / February 5, 2024 / Abbott:
Feb 02, 2024 12:15 pm ET
Can a 'Food as Medicine' Approach Help Manage Diabetes?
In Stockton, Calif., delivering healthy meal boxes to people with diabetes has led to encouraging results.
Feb 01, 2024 08:00 am ET
New Study Shows Mixed Reality Technology for Blood Donation from Abbott and Blood Centers of America Helps Ease Stress, Encourages People to Donate Again
Mixed reality experience allows blood donors to visit a digital world while remaining fully aware of their surroundings for a safe, relaxing donation68.4% of pilot study participants who reported pre-donation anxiety said the mixed reality experience helped ease feelings of anxiety89.2% of donors who tried mixed reality said they were likely to donate blood againInnovation is designed to attract new donors and motivate a younger generation to give bloodABBOTT PARK, Ill., Feb. 1, 2024 /PRNewswire/ -- A new study published online and available in the February print edition of the journal Trans
Jan 31, 2024 08:00 am ET
Abbott Launches New PROTALITY™ Brand to Support Adults on Their Weight Loss Journey
The PROTALITY™ brand provides nutritional support for adults pursuing weight loss in the form of a high-protein nutrition shake featuring a blend of fast- and slow-digesting protein designed to feed muscles for up to seven hoursAs people eat less and lose weight, a portion of what's lost may be from muscle, which is vital to overall health and physical functioningMore than 7 in 10 adults are overweight or have obesity in the U.S. and many turn to diets, whether combined with medication, surgery or calorie restriction, to lose weight and improve overall health1ABBOTT PARK, Ill., Jan. 31, 2024
Jan 25, 2024 08:00 am ET
Abbott Launches World's Smallest Rechargeable System With Remote Programming Capabilities to Treat Movement Disorders¹+
Liberta RC™ deep brain stimulation (DBS) system, recently approved by the U.S. FDA, features NeuroSphere™ Virtual Clinic, which allows for remote programming of the systemSystem offers the longest time between charges of any DBS technology on the market, allowing people with movement disorders to recharge the device only 10 times a year2*ABBOTT PARK, Ill., Jan. 25, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it received approval from the U.S. Food and Drug Administration (FDA) to launch the Liberta RC™ DBS system, the world's smallest rechargeable deep brain stimulation (DBS
Jan 24, 2024 06:30 am ET
Abbott Reports Fourth-Quarter and Full-Year 2023 Results; Issues 2024 Financial Outlook
Fourth-quarter reported sales increased 1.5 percent; organic sales growth for the underlying base business increased 11.0 percentFull-year 2023 reported sales decreased 8.1 percent due to anticipated decline in COVID-19 testing-related sales; organic sales growth for the underlying base business increased 11.6 percentFull-year 2023 GAAP diluted EPS of $3.26; adjusted diluted EPS of $4.44R&D pipeline continues to deliver steady cadence of new productsABBOTT PARK, Ill., Jan. 24, 2024 /PRNewswire/ -- Abbott today announced financial results for the fourth quarter ended Dec. 31, 2023.
Jan 18, 2024 01:45 pm ET
Continuing to Lead the Way in Sustainability
Abbott earns top overall industry score for 11 years, leads in health access on global sustainability benchmark DJSI.
Jan 18, 2024 08:00 am ET
Abbott Announces First Global Procedures in a Clinical Trial of its Volt™ Pulsed Field Ablation System to Treat Patients with Abnormal Heart Rhythms
Abbott's Volt™ Pulsed Field Ablation System is designed to provide a new therapy option for people battling heart rhythm disorders such as atrial fibrillationPulsed field ablation – or PFA – uses high energy electrical pulses for ablation procedures that may offer benefits to target and treat tissue in the heartAbbott's Volt PFA System is designed to overcome limitations of first-generation PFA systems by providing physicians a clearer indication of contact between the Volt PFA Catheter and targeted tissueABBOTT PARK, Ill., Jan. 18, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the
Jan 08, 2024 08:00 am ET
Tandem Diabetes Care’s t:slim X2™ Insulin Pump is the First Automated Insulin Delivery System to Integrate with Abbott’s New FreeStyle Libre® 2 Plus Sensor
Abbott (NYSE: ABT), the global health care company, and Tandem Diabetes Care, Inc. (NASDAQ: TNDM)
Jan 03, 2024 08:00 am ET
Abbott Hosts Conference Call for Fourth-Quarter Earnings
ABBOTT PARK, Ill., Jan. 3, 2024 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2023 financial results on Wednesday, Jan. 24, before the market opens.
Dec 18, 2023 08:00 am ET
Abbott to Present at J.P. Morgan Healthcare Conference
ABBOTT PARK, Ill., Dec. 18, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 42nd annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 9, 2024. Robert B. Ford, chairman and chief executive officer, will present at 11 a.m. Central time.
Dec 15, 2023 10:25 am ET
Abbott Increases Quarterly Dividend for 52nd Consecutive Year
Dividend increased by 7.8%400th consecutive quarterly dividend to be paid by Abbott since 1924Company continues to deliver strong shareholder returns and top-tier growthABBOTT PARK, Ill., Dec. 15, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 55 cents per share, an increase of 7.8%.
Nov 13, 2023 08:00 am ET
Late-Breaking Data Show an Aspirin-Free Medication Regimen Benefits People with Abbott's HeartMate 3™ Heart Pump
New data from the ARIES trial show for the first time that an aspirin-free regimen can improve outcomes for people living with the heart pump by reducing hospitalizations without increasing the risk of blood clotsMore than 30,000 people worldwide have received Abbott's life-saving heart pump to overcome advanced heart failureABBOTT PARK, Ill., Nov. 13, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) announced new late-breaking data that show advanced heart failure patients living with its HeartMate 3™ heart pump who didn't receive aspirin as part of their blood-thinning medication regimen experience
Nov 08, 2023 12:30 pm ET
Participants in Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes
ABBOTT PARK, IL & OAKLAND, CA / ACCESSWIRE / November 8, 2023 / Abbott / A study of Abbott's (NYSE:ABT) Healthy Food Rx, a food as medicine program that provides home-delivered medical prescriptions of healthy food to help address diabetes, showed clinically important benefits for people with diabetes. The real-world study, which was conducted by the Public Health Institute's Center for Wellness and Nutrition (PHI CWN) in an active community clinic over a 12-month period, found that Healthy Food Rx participants had lower A1C levels,
Nov 08, 2023 05:00 am ET
Participants in Abbott's Food as Medicine Program Showed Clinically Significant Improvements in Managing Diabetes
Study by Public Health Institute shows people with diabetes were able to lower A1C levels, better self-manage diabetes, and improve overall diet and food security at 12 monthsAbbott's Healthy Food Rx program provides home-delivered healthy food boxes to help address diabetes; part of broader collaboration to address social barriers and expand access to health in Stockton, Calif.ABBOTT PARK, Ill. and OAKLAND, Calif., Nov. 8, 2023 /PRNewswire/ -- A study of Abbott's (NYSE: ABT) Healthy Food Rx, a food as medicine program that provides home-delivered medical prescriptions of healthy food to hel
Nov 02, 2023 12:45 pm ET
Abbott and Sherri Shepherd: Millions Not Using Affordable Diabetes Technology
ABBOTT PARK, IL / ACCESSWIRE / November 2, 2023 / Abbott (NYSE:ABT) announced 'Countdown at a Crossroads,' which kicks off National Diabetes Awareness Month by taking over the Oculus Center in New York City - the literal "Crossroads of the World" - with an animated installation that features the faces and stories of people impacted by diabetes, including comedian and talk show host Sherri Shepherd.
Nov 02, 2023 09:00 am ET
Abbott Receives FDA Approval for HPV Test to Run on Alinity m, Offering Primary HPV Screening and Assessment of High-Risk Cancer-Causing Types of HPV
According to the U.S. Centers for Disease Control (CDC), most sexually active adults will experience HPV infections; new test detects those HPV genotypes that could lead to cancerAbbott's new HPV test uses molecular technology to provide genotype determination on the 14 high-risk, cancer-causing types of HPVThe test is one of the fewi HPV tests approved for use as a primary screen for cervical cancer as recommended by professional guidelines ABBOTT PARK, Ill., Nov. 2, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) has received U.S. Food and Drug Administration (FDA) approval for its molecular huma
Nov 01, 2023 01:00 pm ET
Abbott and Damar Hamlin Team Up To Build Heart Health Community With New Heartmates Program
ABBOTT PARK, IL / ACCESSWIRE / November 1, 2023 / Abbott (NYSE:ABT), a global leader in heart health, announced today the Abbott HeartMates program, a new initiative that will kick off with professional football player Damar Hamlin as its first ambassador.
Nov 01, 2023 08:28 am ET
Abbott and Sherri Shepherd: Millions Not Using Affordable Diabetes Technology
Abbott and Shepherd aim to raise awareness of the rising rates of diabetes diagnoses and how access to continuous glucose monitoring (CGM) systems can reduce diabetes-related complications1, provide better health outcomes, and improve quality of living2Television host and diabetes advocate Sherri Shepherd unveils one-of-a-kind animated installation at the Oculus Center in New York City featuring herself alongside the faces and stories of people like her who are thriving despite their diagnosisEvery visit to www.Crossroads.Abbott during November's National Diabetes Awareness Month will trigge
Oct 31, 2023 08:00 am ET
Abbott and Damar Hamlin Team Up to Build Heart Health Community with New HeartMates Program
HeartMates will create a supportive and empowering community for people impacted by heart conditions, leveraging Abbott's leadership in cardiovascular careProfessional football player and heart health advocate Damar Hamlin joins Abbott to kick off the HeartMates programHeart disease impacts over 100 million Americans, nearly half of U.S. adults1Abbott will host a media conference call on Tuesday, Oct. 31, at 5 p.m. ET with Hamlin to discuss the programABBOTT PARK, Ill., Oct. 31, 2023 /PRNewswire/ -- Abbott (NYSE: ABT), a global leader in heart health, announced today the Abbott HeartMates pr
Oct 30, 2023 03:15 pm ET
Tackling Student Loans and Saving - Together
Our new blueprint makes it easier for companies to help their people pay off school debt and save for retirement.
Oct 26, 2023 06:00 pm ET
Ninety-One Percent of Young Adults With Student Loans Say Financial Stress Is Impacting Their Wellness
Abbott Launches Blueprint of Award-Winning Program To Help Companies Tackle This Problem
Oct 26, 2023 09:00 am ET
Ninety-One Percent of Young Adults With Student Loans Say Financial Stress is Impacting Their Wellness -- Abbott Launches Blueprint of Award-Winning Program to Help Companies Tackle This Problem
New survey by Morning Consult on behalf of Abbott shows student loans are having a profound and far-reaching impact on young adults and their planning for the future91% say financial stress is impacting their mental, physical wellness and student loan debt is a key driver of this financial stress94% are interested in a workplace benefit in which they get an employer-provided 401(k) contribution as they pay off their school loansAbbott's new blueprint of its award-winning Freedom 2 Save program helps companies create a proven student loan benefit program for their peopleABBOTT PARK, Ill., Oct
Oct 25, 2023 02:30 pm ET
Late-Breaking Data Show Esprit™ BTK Drug-Eluting Resorbable Scaffold Reduces Chronic Limb-Threatening Ischemia Progression Compared to the Standard of Care
Abbott's new investigational drug-eluting Esprit BTK (below-the-knee) resorbable scaffold is made of naturally dissolving material that disappears over time after it's opened a clogged arteryThere is a significant need for more treatments: there are currently no drug-eluting stents, drug-coated balloons or bare-metal stents approved for below the knee (BTK) use in the U.S.Abbott's landmark LIFE-BTK randomized clinical trial met its primary safety and effectiveness endpoints, demonstrating that Esprit BTK offers significant advancements in opening and keeping blocked arteries below-the-knee o
Oct 25, 2023 12:00 pm ET
Can Health Tech Be the Most Helpful Technology of All?
NORTHAMPTON, MA / ACCESSWIRE / October 25, 2023 / Abbott:
Oct 24, 2023 06:18 pm ET
Late-Breaking Data Showcase the Benefits of Abbott's Minimally Invasive Devices for People With Leaky Heart Valves
New data presented at Transcatheter Cardiovascular Therapeutics (TCT) 2023 from the TRILUMINATE™ pivotal trial confirm safety, effectiveness and improvements in quality of life when treating tricuspid regurgitation (a leaky valve) with TriClip™, an investigational device in the U.S.One-year outcomes from the EXPAND G4 study, simultaneously published in JACC: Cardiovascular Interventions, reinforce durable safety and effectiveness of MitraClip™ with significant mitral regurgitation reductionABBOTT PARK, Ill., Oct. 24, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced data from late-brea
Oct 24, 2023 12:00 pm ET
Sharing the Access Code to Help Open Up Diabetes Care
NORTHAMPTON, MA / ACCESSWIRE / October 24, 2023 / Abbott
Oct 19, 2023 09:15 am ET
Abbott Recognized on Fortune Change the World List
Fortune honors Abbott for groundbreaking Freedom 2 Save program, promoting financial wellness for employees.
Oct 18, 2023 07:30 am ET
Abbott Reports Third-Quarter 2023 Results and Raises Midpoint of Full-Year EPS Guidance Range
Sales of $10.1 billion driven by strong underlying base business performance Reported sales decreased 2.6 percent due to anticipated decline in COVID-19 testing-related sales versus prior yearOrganic sales growth for underlying base business of 13.8 percent, reflects double-digit growth in each of the four major businessesABBOTT PARK, Ill., Oct. 18, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2023.
Sep 27, 2023 09:00 am ET
Abbott Hosts Conference Call for Third-Quarter Earnings
ABBOTT PARK, Ill., Sept. 27, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2023 financial results on Wednesday, Oct. 18, before the market opens.
Sep 26, 2023 08:35 am ET
Abbott Shares Progress on Sustainability Performance, Including Company’s Priority of Innovating for Greater Health Access
NORTHAMPTON, MA / ACCESSWIRE / September 26, 2023 / Abbott recently released its 2022 Global Sustainability Report, highlighting efforts to help the greatest number of people live better, healthier lives. The comprehensive report details disclosures on the company's performance and impact across all areas of its 2030 Sustainability Plan. This includes a focus on how Abbott is intentionally innovating for access and affordability to make their life-saving technologies available to more people who need them worldwide.
Sep 22, 2023 08:48 am ET
Abbott Completes Acquisition of Bigfoot Biomedical
ABBOTT PARK, Ill., Sept. 22, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Bigfoot Biomedical, a leader in developing smart insulin management systems for people with diabetes.
Sep 21, 2023 12:02 pm ET
Abbott Declares 399th Consecutive Quarterly Dividend
ABBOTT PARK, Ill., Sept. 21, 2023 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 51 cents per share.
Sep 20, 2023 08:00 am ET
Abbott Broadens Access to Cutting-Edge Biosimilars in Key Emerging Markets
Abbott to commercialize several biosimilar molecules in key emerging markets in Latin America, Southeast Asia, the Middle East and AfricaSpain-based global biotech leader mAbxience Holdings S.L. to develop, manufacture and supply the biosimilar moleculesFirst molecules expected to launch as early as 2025, offering new treatment options that leverage the latest in scientific breakthroughs for people in emerging marketsABBOTT PARK, Ill., Sept. 20, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) announced today an agreement with Spain-based global biotech leader mAbxience Holdings S.L. to commercialize
Sep 19, 2023 10:30 am ET
Canadian First - Abbott's TactiFlex™ Ablation Catheter Used to Treat AFib
Abbott introduced the world's first ablation catheter with a flexible tip and contact force technology, used to perform an ablation procedure to treat atrial fibrillation (AFib)First successful treatment in Canada - Abbott's innovative technology enables physicians to have better visualization allowing for more accuracy and precision, leading to reduced procedure times and better safetyMISSISSAUGA, ON, Sept. 19, 2023 /CNW/ -- Abbott (NYSE: ABT) today announced that the company's TactiFlex™ Ablation Catheter, Sensor Enabled™, the world's first ablation catheter with a flexible tip and contact
Sep 19, 2023 08:00 am ET
Abbott and WeightWatchers Connected App Experience is Now Available for People Living with Diabetes
The #1 prescribed continuous glucose monitoring (CGM) system1 now connects to the #1 doctor-recommended weight management plan2 to help people living with diabetes understand how food and activity impact their glucose levelsWeightWatchers Diabetes-Tailored Plan members can now see key glucose data3,4,5 from Abbott's FreeStyle Libre® 2 system within the WW app6 ABBOTT PARK, Ill. and NEW YORK, Sept. 19, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) and WW International, Inc. (NASDAQ: WW), known as WeightWatchers, announced today the availability of a connected app to help people living with diabetes
Sep 15, 2023 10:10 am ET
Virus Hunt Zooms In To Focus on New Potential Pandemics
NORTHAMPTON, MA / ACCESSWIRE / September 15, 2023 / Abbott
Sep 13, 2023 09:30 am ET
One Size Does Not Fit All: The Future of Clinical Trials
NORTHAMPTON, MA / ACCESSWIRE / September 13, 2023 / Abbott
Sep 11, 2023 08:30 am ET
Less Is More: Abbott’s Approach to Packaging Innovation
NORTHAMPTON, MA / ACCESSWIRE / September 11, 2023 / Abbott
Sep 07, 2023 01:15 pm ET
Jul 20, 2023 07:30 am ET
Abbott Reports Second-Quarter 2023 Results; Increases Outlook For Underlying Base Business
Sales of $10.0 billion driven by strong underlying base business performance Reported sales decreased 11.4 percent due to anticipated decline in COVID-19 testing-related sales versus prior yearOrganic sales growth for underlying base business of 11.5 percent, led by Medical Devices, Established Pharmaceuticals and NutritionContinues to strengthen portfolio with new product approvals and expanded reimbursement coverageABBOTT PARK, Ill., July 20, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the second quarter ended June 30, 2023.
Jul 10, 2023 04:15 pm ET
Shaping the Future of Abbott and Healthcare
NORTHAMPTON, MA / ACCESSWIRE / July 10, 2023 / At Abbott, sustainability starts with our purpose - helping people lead fuller lives through better health. That's how Abbott can make the biggest impact on people's lives and deliver sustainable, responsible business growth in the years to come.
Jul 05, 2023 09:00 am ET
Abbott Receives FDA Approval for World's First Dual-Chamber Leadless Pacemaker
Abbott's breakthrough technology enables the world's first beat-to-beat, wireless communication and synchronization between two leadless pacemakers, which are smaller than a AAA batteryLeadless pacemakers provide a new minimally invasive option that will revolutionize care for more people in the U.S. who need pacing to treat a variety of slow or abnormal heart rhythmsApproval comes on the heels of recent late-breaking clinical trial data showing that the AVEIR™ DR leadless pacemaker system is safe and effective at treating abnormal heart rhythmsABBOTT PARK, Ill., July 5, 2023 /PRNewswire/ --
Jun 29, 2023 09:00 am ET
Abbott Hosts Conference Call for Second-Quarter Earnings
ABBOTT PARK, Ill., June 29, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its second-quarter 2023 financial results on Thursday, July 20, before the market opens.
Jun 28, 2023 02:15 pm ET
The American Diabetes Association and Abbott Collaborate on First-of-Its-Kind Therapeutic Nutrition Program for People With Diabetes
ARLINGTON, VA and ABBOTT PARK, IL / ACCESSWIRE / June 28, 2023 / Abbott:
Jun 22, 2023 09:00 am ET
Abbott's FreeStyle Libre® 2 Receives National Reimbursement in France for All People with Diabetes Who Use Insulin¹
First and only continuous glucose monitoring system to be nationally reimbursed in France for people who use once-daily (basal) insulin1Expanded reimbursement facilitates wider access to continuous glucose monitoring (CGM) systems, serving a greater population of people living with diabetesFrance is the first country in Europe to grant national reimbursement for people who use basal insulin, following similar reimbursement expansions in Japan and the U.S. (Medicare)ABBOTT PARK, Ill., June 22, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the French health authority has approve
Jun 09, 2023 10:55 am ET
Abbott Declares 398th Consecutive Quarterly Dividend
ABBOTT PARK, Ill., June 9, 2023 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 51 cents per share.
Jun 06, 2023 01:40 pm ET
Abbott and Real Madrid's Goal: Beating Malnutrition
NORTHAMPTON, MA / ACCESSWIRE / June 6, 2023 / Abbott
Jun 01, 2023 04:15 pm ET
Abbott, Real Madrid and the Real Madrid Foundation Band Together To ‘Beat Malnutrition’ Globally Through New Campaign
ABBOTT PARK, IL / ACCESSWIRE / June 1, 2023 / Abbott (NYSE:ABT), Real Madrid and the Real Madrid Foundation announced the launch of the 'Beat Malnutrition' campaign during Real Madrid's final match weekend of the 2022/2023 LaLiga season. The new campaign empowers communities to help children reach their full potential through nutrition education and malnutrition screening and furthers Abbott's partnership with Real Madrid and the Real Madrid Foundation to reduce global childhood malnutrition.
May 31, 2023 09:00 am ET
Abbott, Real Madrid and the Real Madrid Foundation Band Together to 'Beat Malnutrition' Globally Through New Campaign
Abbott, Real Madrid and the Real Madrid Foundation launch 'Beat Malnutrition' campaign as part of a sustained collaboration urging communities to work together to reduce malnutritionCampaign will supply malnutrition screening tools to local communities and provide funding for malnutrition programs at Real Madrid Foundation Social Sports SchoolsAbbott study finds only 36% of U.S. parents were extremely confident that they could identify malnutrition in their child, while just 29% have consulted with a doctor/nutritionist about malnutritionABBOTT PARK, Ill., May 31, 2023 /PRNewswire/ -- Abbott
May 24, 2023 09:00 am ET
European Study Finds the Abbott CardioMEMS Sensor Results in Improved Quality of Life and 44% Reduction in Heart Failure Hospitalizations
MONITOR-HF is the third randomized, controlled trial globally to show a significant health benefit for indicated heart failure patientsCardioMEMS is a paperclip-sized sensor that can remotely flag to a patient's clinical team the early warning signs of worsening heart failureABBOTT PARK, Ill., May 24, 2023 /PRNewswire/ -- New data presented from an investigator-sponsored European trial found managing indicated1 heart failure patients with Abbott's CardioMEMS™ HF System resulted in a significant1 improvement in patient-reported quality-of-life scores as early as three months after use with th
May 20, 2023 09:18 am ET
Abbott Unveils Late-Breaking Data Showing the World's First Dual-Chamber Leadless Pacemaker Study Met All Three Primary Endpoints
Abbott's AVEIR™ DR i2i™ IDE study is the industry's first prospective study on the safety and performance of the world's first dual-chamber leadless pacemakerThe study successfully met all three of its primary safety and performance endpointsAbbott's investigational AVEIR DR leadless pacemakers have been submitted for evaluation by the U.S. FDANEW ORLEANS, May 20, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced late-breaking results from the AVEIR™ dual-chamber (DR) i2i™ Investigational Device Exemption (IDE) study, a large-scale study to assess the world's first dual-chamber leadles
May 19, 2023 10:30 am ET
May 19, 2023 09:00 am ET
Abbott Receives FDA Approval for TactiFlex™ Ablation Catheter for Treatment of Abnormal Heart Rhythm
TactiFlex™ Ablation Catheter, Sensor Enabled™, is the world's first ablation catheter designed with a unique flexible electrode tip and contact force sensing to treat patients with atrial fibrillationWhen used with Abbott's EnSite™ X EP System, physicians have better visualization allowing for more accuracy and precision with the TactiFlex catheter, leading to reduced procedure times and better safetyABBOTT PARK, Ill., May 19, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's TactiFlex™ Ablation Catheter, Senso
May 18, 2023 09:00 am ET
Abbott Receives FDA Clearance for Assert-IQ™ Insertable Cardiac Monitor to Help Doctors Monitor People's Heart Rhythms Long-Term
Abbott's Assert-IQ offers the world's longest battery life† for an insertable cardiac monitor (ICM)The latest addition to Abbott's portfolio of connected health devices, the Assert-IQ ICM offers long-term monitoring and remote programming to improve connectivity to patientsThe device provides continuous monitoring for abnormal heart rhythms while offering tools designed to help improve data management and workflow within a physician's practiceABBOTT PARK, Ill., May 18, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced its Assert-IQ™ insertable cardiac monitor (ICM) has received U.S. Fo
May 16, 2023 09:00 am ET
Abbott Receives FDA Approval for Its Spinal Cord Stimulation Systems to Treat Chronic Back Pain in People Who Have Limited Surgical Options
FDA approval was backed by Abbott's DISTINCT study, the largest randomized controlled trial for spinal cord stimulation (SCS) in people with chronic back pain when surgery is not an optionResults for the first 200 patients demonstrated that people who used the company's SCS products experienced significant relief and improvements in pain, function, quality of life and psychological status1,2Prior to enrollment in the study, participants suffered from severe, disabling chronic back pain for an average of 12.8 years2ABBOTT PARK, Ill., May 16, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) announced t
May 11, 2023 12:15 pm ET
May 11, 2023 09:00 am ET
Abbott Announces New Partnerships and Programs to Advance its Diversity in Clinical Trials Initiative
New efforts focus on research infrastructure, continued training of diverse clinical research personnel and improved diversity within Abbott's own clinical trialsAbbott's Diversity in Clinical Trials initiative aligns with the company's continued focus for greater health equity, expanded access, affordability and removing barriers to life-saving technology and innovationThe new programs build on a successful first year of the multi-million-dollar corporate initiativeABBOTT PARK, Ill., May 11, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced a series of new programs within its multi-mi
Apr 27, 2023 04:10 pm ET
Abbott Completes Acquisition of Cardiovascular Systems, Inc.
ABBOTT PARK, Ill., April 27, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced it has completed the acquisition of Cardiovascular Systems, Inc. (CSI), a medical device company with an innovative atherectomy system used in treating peripheral and coronary artery disease.
Apr 27, 2023 12:00 pm ET
Climate Change: The Impact on Viral Outbreaks
NORTHAMPTON, MA / ACCESSWIRE / April 27, 2023 / Abbott
Apr 25, 2023 05:54 pm ET
Cytek Biosciences Set to Join S&P SmallCap 600
NEW YORK, April 25, 2023 /PRNewswire/ -- Cytek Biosciences Inc (NASD:CTKB) will replace Cardiovascular Systems Inc. (NASD:CSII) in the S&P SmallCap 600 effective prior to the opening of trading on Monday, May 1. S&P 500 and 100 constituent Abbott Laboratories (NYSE:ABT) is acquiring Cardiovascular Systems in a deal expected to be completed soon, pending final closing conditions.
Apr 25, 2023 09:00 am ET
Abbott's Life Support System Receives New FDA Clearances to Help Doctors Treat More Critically Ill Patients
Abbott's CentriMag™ Blood Pump, previously cleared for use up to six hours, now can be used to provide longer-term life support to critically ill patients, providing doctors more time to make critical care decisionsAbbott's CentriMag™ Pre-connected Pack, which combines a blood pump and oxygenator to form a life support circuit, also received FDA clearance for life support lasting less than six hours, helping physicians provide urgent critical care more efficiently and in fewer stepsABBOTT PARK, Ill., April 25, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced two new clearances from th
Apr 20, 2023 03:00 pm ET
Abbott and New Global Consortium Partnership Address Viral Outbreaks Caused by Climate Change
ABBOTT PARK, IL / ACCESSWIRE / April 20, 2023 / Abbott (NYSE:ABT) announced today that it is partnering with the Climate Amplified Disease and Epidemics (CLIMADE) consortium, a group of more than 100 global scientists in public health agencies, academia and industry focused on using data science technology and diagnostic testing to assess and potentially mitigate the impact climate change has on disease outbreaks.
Apr 20, 2023 09:00 am ET
Abbott and New Global Consortium Partnership Address Viral Outbreaks Caused by Climate Change
Abbott is joining the Climate Amplified Disease and Epidemics (CLIMADE) consortium, which will use data science to predict, track and control diseases that may be amplified by climate changeA changing climate may increase the spread of both known and unknown viruses, particularly those transmitted by water or animals carrying diseasesCLIMADE's initial work will start with disease surveillance in Africa and expand to countries often impacted by infectious disease outbreaks caused by climate changeABBOTT PARK, Ill., April 20, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that it is p
Apr 19, 2023 09:46 am ET
Thinking about trading options or stock in Legend Biotech, Abbott Laboratories, Johnson & Johnson, Coca-Cola, or Tesla?
NEW YORK, April 19, 2023 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for LEGN, ABT, JNJ, KO, and TSLA.
Apr 19, 2023 07:15 am ET
Abbott Reports First-Quarter 2023 Results; Increases Outlook For Underlying Base Business
Sales of $9.7 billion driven by strong underlying base business performance Reported sales decreased 18.1 percent due to anticipated decline in COVID-19 testing-related sales versus prior yearOrganic sales growth for underlying base business of 10.0 percent, led by Medical Devices, Established Pharmaceuticals and NutritionABBOTT PARK, Ill., April 19, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the first quarter ended March 31, 2023.
Apr 17, 2023 08:00 am ET
Abbott's FreeStyle Libre® Continuous Glucose Monitoring Systems Obtain Significantly Expanded Coverage for Medicare Beneficiaries
The Medicare program has expanded access to continuous glucose monitoring systems like the FreeStyle Libre 2 system and the FreeStyle Libre 14 day system for insulin-using1 Medicare beneficiaries with diabetes, removing the prior requirement of multiple daily insulin injectionsMedicare beneficiaries with diabetes and a history of problematic hypoglycemia2 may also be eligible to have their FreeStyle Libre 2 system or FreeStyle Libre 14 day system covered for reimbursementAbbott is working to get the latest-generation FreeStyle Libre 3 system added to Medicare's list of covered systems as soo
Apr 14, 2023 09:00 am ET
FDA Clears Reader for Abbott's FreeStyle Libre® 3 System
The FreeStyle Libre 3 system is the latest generation in Abbott's FreeStyle Libre portfolio – the most prescribed and affordable integrated continuous glucose monitoring (iCGM) system in the United States1,2With a standalone reader, Abbott is working3 to have the FreeStyle Libre 3 system available to Medicare beneficiaries who use insulin4ABBOTT PARK, Ill., April 14, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared a reader for its FreeStyle Libre® 3 integrated continuous glucose monitoring (iCGM) system, which features the
Mar 29, 2023 09:00 am ET
Abbott Hosts Conference Call for First-Quarter Earnings
ABBOTT PARK, Ill., March 29, 2023 /PRNewswire/ -- Abbott will announce its first-quarter 2023 financial results on Wednesday, April 19, 2023, before the market opens.
Mar 28, 2023 02:30 pm ET
Don’t Mess With Your 'Melon': Abbott and the Brain Injury Association of America Urge 'If You Hit Your Head, Get It Checked' In New Public Service Announcement
ABBOTT PARK, IL and FAIRFAX, VA / ACCESSWIRE / March 28, 2023 / Concussion Awareness Now, a coalition of nearly 20 advocacy groups founded by Abbott and the Brain Injury Association of America, unveiled a new public service campaign to draw attention to concussions and the importance of seeking care.
Mar 23, 2023 11:45 am ET
Seeking Answers About Transgender Heart Health
NORTHAMPTON, MA / ACCESSWIRE / March 23, 2023 / Abbott
Mar 23, 2023 09:00 am ET
Don't Mess with Your 'Melon': Abbott and the Brain Injury Association of America Urge 'If You Hit Your Head, Get it Checked' in New Public Service Announcement
The Concussion Awareness Now campaign raises awareness both about the common, everyday ways concussions most often happen and the importance of getting concussions evaluatedConcussion Awareness Now is a coalition of nearly 20 advocacy groups, founded by Abbott and the Brain Injury Association of America, with Rebel Wilson as the group's inaugural spokespersonThe campaign addresses the fact that more than half of people who suspect they have a concussion never get it checked and features a family of characters called the MelonsABBOTT PARK, Ill., and FAIRFAX, Va., March 23, 2023 /PRNewswire/ -
Mar 22, 2023 02:35 pm ET
Abbott: Clean, Accessible Water for a Healthy Future
NORTHAMPTON, MA / ACCESSWIRE / March 22, 2023 / Abbott
Mar 20, 2023 08:00 am ET
InspireMD Announces Promotion of Andrea Tommasoli to Chief Operating Officer
InspireMD, Inc. (Nasdaq: NSPR), developer of the CGuard™ Embolic Prevention Stent System (EPS) for the prevention of stroke, today announced that it has promoted Andrea Tommasoli to Chief Operating Officer. Mr. Tommasoli formerly served as the...
Mar 03, 2023 07:29 pm ET
ABBOTT LABORATORIES INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Abbott Laboratories - ABT
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Abbott Laboratories (NYSE: ABT).
Feb 22, 2023 10:33 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO)
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Feb 17, 2023 11:26 am ET
Abbott Declares 397th Consecutive Quarterly Dividend
ABBOTT PARK, Ill., Feb. 17, 2023 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 51 cents per share.
Feb 14, 2023 11:04 am ET
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: NUVASIVE (Nasdaq – NUVA), Oak Street Health (NYSE – OSH), Argo Group International Holdings, Ltd. (NYSE - ARGO)
Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky ([email protected]) or Marc Ackerman ([email protected]) at 855-576-4847. There is no...
Feb 09, 2023 06:31 pm ET
SHAREHOLDER ALERT: Weiss Law Investigates Cardiovascular Systems, Inc.
NEW YORK, Feb. 9, 2023 /PRNewswire/ -- Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cardiovascular Systems, Inc. ("Cardiovascular Systems" or the "Company") (NASDAQ: CSII), in connection with the proposed acquisition of the Company by Abbott Laboratories (NYSE: ABT). Under the terms of the merger agreement, the Company's shareholders will receive $20.00 in cash for each share of Cardiovascular Systems owned. The transaction is valued at approximately $890 million.
Feb 08, 2023 05:05 pm ET
Abbott to Acquire Cardiovascular Systems, Inc.
Abbott will gain an innovative, complementary solution in treating vascular disease through CSI's leading atherectomy system, which prepares vessels for angioplasty or stenting to restore blood flowCSI's offering will support Abbott's ability to provide better care for patients with peripheral and coronary artery diseaseABBOTT PARK, Ill. and ST. PAUL, Minn., Feb. 8, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) and Cardiovascular Systems, Inc. (CSI), today announced a definitive agreement for Abbott to acquire CSI, a medical device company with an innovative atherectomy system used in treating per
Jan 26, 2023 08:00 am ET
FDA Approves Abbott's Spinal Cord Stimulation for People Living with Painful Diabetic Peripheral Neuropathy
The new indication for Abbott's Proclaim™ XR SCS system provides a non-medication option for people with painful diabetic peripheral neuropathySpinal cord stimulation is proven to be more effective than conventional medical management in the treatment of chronic pain1,2ABBOTT PARK, Ill., Jan. 26, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved its Proclaim™ XR spinal cord stimulation (SCS) system to treat painful diabetic peripheral neuropathy (DPN), a debilitating complication of diabetes. The Proclaim XR SCS system can p
Jan 25, 2023 06:30 am ET
Abbott Reports Fourth-Quarter and Full-Year 2022 Results; Issues 2023 Financial Outlook
Fourth-quarter sales of $10.1 billion; full-year 2022 sales of $43.7 billionFull-year 2022 sales growth of 1.3 percent; organic sales growth of 6.4 percentFull-year 2022 GAAP diluted EPS of $3.91; adjusted diluted EPS of $5.34Continues to strengthen portfolio with steady cadence of new product approvalsABBOTT PARK, Ill., Jan. 25, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2022.
Jan 19, 2023 09:00 pm ET
ABBOTT ALERT: Bragar Eagel & Squire, P.C. is Investigating Abbott Laboratories on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Abbott Laboratories (NYSE: ABT) on behalf of long-term stockholders following a class action complaint that was filed against Abbott on August 31, 2022 with a Class Period from February 19, 2021, to June 8, 2022. Our investigation concerns whether the board of directors of Abbott have breached their fiduciary duties to the company.
Jan 17, 2023 08:00 am ET
Abbott Receives FDA Approval for Navitor™, a Next-Generation TAVI System Designed to Treat Aortic Stenosis
Abbott's new Navitor device features advancements to improve patient care, including reducing or eliminating risk of blood leakage around valve implant Transcatheter aortic valve implantation (TAVI) offers minimally invasive alternative to surgery for people with aortic stenosis, a common and life-threatening heart valve disease ABBOTT PARK, Ill., Jan. 17, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the company's latest-generation transcatheter aortic valve implantation (TAVI) system, Navitor™, to treat people with s
Jan 06, 2023 08:00 pm ET
Abbott, Blood Centers of America Launch First-of-its-Kind Mixed Reality Experience for Use During Blood Donation
Mixed reality offers donors an innovative, immersive digital experience while giving bloodThe Abbott technology is one of the first-ever, consumer-focused mixed reality applications completely controlled through eye trackingInnovation aims to improve the experience and attract new, younger blood donors by adding an element of high-tech mixed realityLAS VEGAS, Jan. 6, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) and Blood Centers of America are unveiling an innovative new mixed reality experience for use during blood donation.
Jan 04, 2023 08:00 am ET
Abbott Hosts Conference Call for Fourth-Quarter Earnings
ABBOTT PARK, Ill., Jan. 4, 2023 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2022 financial results on Wednesday, Jan. 25, 2023, before the market opens.
Dec 21, 2022 08:00 am ET
Abbott's FreeStyle Libre® 3 Integrated with Automated Insulin Delivery System mylife™ Loop in Germany
First automated insulin delivery (AID) system in the world to work with Abbott's FreeStyle Libre® 3 sensorAutomated process streamlines and improves daily diabetes management for people who are on insulin therapy1Hybrid closed-loop system mylife™ Loop incorporates technology from two partners: CamDiab's algorithm automatically adjusts insulin dosage on Ypsomed's insulin pump, mylife™ YpsoPump®, based on accurate2, real-time glucose information from FreeStyle Libre 3 sensorABBOTT PARK, Ill., Dec. 21, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its FreeStyle Libre® 3 sensor is
Dec 20, 2022 08:00 am ET
Abbott to Present at J.P. Morgan Healthcare Conference
ABBOTT PARK, Ill., Dec. 20, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 10, 2023. Robert B. Ford, chairman and chief executive officer, will present at 11 a.m. Central time.
Dec 19, 2022 08:00 am ET
Abbott Launches the World's Smallest Implantable, Rechargeable Spinal Cord Stimulation System for Chronic Pain
The U.S. Food and Drug Administration (FDA) approved Abbott's Eterna™ spinal cord stimulation (SCS) system for the treatment of chronic painThis neuromodulation device provides an optimized experience with the ability to wirelessly charge as few as five times per year, the lowest recharge burden compared to other rechargeable SCS systems §1,2,3ABBOTT PARK, Ill., Dec. 19, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced the U.S. Food and Drug Administration (FDA) approval of the company's Eterna™ spinal cord stimulation (SCS) system – the smallest implantable, rechargeable spinal cord
Dec 13, 2022 07:30 am ET
Abbott and the Brain Injury Association of America launch Concussion Awareness Now coalition; team up with Rebel Wilson to raise awareness on seriousness of concussions
Concussion Awareness Now is comprised of nearly 20 advocacy groups focused on brain injury and will work to raise awareness about the importance of diagnosis and treatment for concussionsThe vast majority of concussions happen in everyday accidents, and over half of people who suspect they have a concussion never get it checkedRebel Wilson sustained a concussion while on set producing and acting in a movie and is sharing her personal story to help raise awarenessABBOTT PARK, Ill., and WASHINGTON, Dec. 13, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) and the Brain Injury Association of America ann
Dec 09, 2022 09:48 am ET
Abbott Increases Quarterly Dividend, Marking 51 Consecutive Years of Dividend Growth
Dividend increased by 8.5%Reflects Abbott's longstanding commitment to sustainable growth and shareholder returnsABBOTT PARK, Ill., Dec. 9, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 51 cents per share, an increase of 8.5%.
Nov 17, 2022 08:00 am ET
Abbott Receives Three CES 2023 Innovation Awards for Advancements in Health Technology
The Consumer Technology Association (CTA) awards Abbott multiple CES 2023 Innovation Awards for industry-leading health technologiesAbbott's Aveir™ single-chamber (VR) leadless pacemaker, Proclaim™ Plus SCS system, Alinity® m Monkeypox PCR test honoredOther recent Abbott innovation honors include Abbott's FreeStyle Libre® technology named the best medical technology in the last 50 years by the Galien FoundationABBOTT PARK, Ill., Nov. 17, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) has been recognized by the Consumer Technology Association (CTA) with three CES 2023 Innovation Awards for its life-
Nov 07, 2022 10:45 am ET
MedTech Market Leaders Share Their Long-Term Business Strategy at CECP's CEO Investor Forum @ The MedTech Conference
Three CEOs representing over $372 billion in market capitalization set the context for the future engaging with institutional investors
Oct 31, 2022 03:11 pm ET
Oct 31, 2022 11:00 am ET
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Abbott Laboratories (ABT) Investors of Class Action and to Actively Participate
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Abbott Laboratories (“Abbott” or “the Company”) (NYSE: ABT) and certain of its officers, on behalf of all persons and entities that purchased, or otherwise acquired Abbott securities between February 19, 2021 to June 8, 2022, both dates inclusive (the “Class Period”). Such investors are encouraged to join this case by visiting the firm’s site:
Oct 31, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Abbott Investors of a Lead Plaintiff Deadline of October 31, 2022
NEW YORK, Oct. 31, 2022 /PRNewswire/ -- Attention Abbott Laboratories ("Abbott") (NYSE: ABT) shareholders:
Oct 30, 2022 06:30 pm ET
ABT IMPORTANT DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Abbott Laboratories Investors to Secure Counsel Before Important October 31 Deadline in Securities Class Action – ABT
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the “Class Period”), of the important October 31, 2022...
Oct 30, 2022 03:09 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT
Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Oct 28, 2022 10:50 pm ET
ABBOTT LABORATORIES 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuit Against
Kahn Swick & Foti, LLC ("KSF") and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they purchased the Company’s shares between February 19, 2021 to June 8, 2022, inclusive (the “Class Period”). This action is pending in the United States District Court for the Northern District of Illinois.
Oct 28, 2022 09:00 am ET
Abbott's FreeStyle Libre® is Named Best Medical Technology in Last 50 Years by the Galien Foundation
Abbott's FreeStyle Libre honored as the "best of the best" since 1970 during the Prix Galien Golden Jubilee AwardsRevolutionary FreeStyle Libre technology has transformed the lives of approximately 4.5 million people1 living with diabetes globallyABBOTT PARK, Ill., Oct. 28, 2022 /PRNewswire/ -- The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, named Abbott's FreeStyle Libre® continuous glucose monitoring technology as the "Best Medical Technology" of the last 50 years during its Prix Galien Golden Jubilee Awards ceremony on Oct. 27 in Ne
Oct 28, 2022 05:45 am ET
ABT SHAREHOLDER ALERT: Jakubowitz Law Reminds Abbott Shareholders of a Lead Plaintiff Deadline of October 31, 2022
NEW YORK, Oct. 28, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Abbott Laboratories (NYSE: ABT).
Oct 27, 2022 08:00 am ET
Abbott Investors: Please Contact the Portnoy Law Firm to Recover Your Losses; Last Days to Actively Participate in the Case; October 31, 2022
The Portnoy Law Firm advises Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT) investors that a class action has been filed on behalf of investors. Abbott investors with over $500,000 in losses on their investment are encouraged...
Oct 27, 2022 05:45 am ET
ABT LAWSUIT ALERT: Levi & Korsinsky Notifies Abbott Laboratories Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Oct. 27, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT) of a class action securities lawsuit.
Oct 26, 2022 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Abbott Laboratories - ABT
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Abbott Laboratories (NYSE: ABT), if they purchased the Company’s shares between February 19, 2021 to June 8, 2022, inclusive (the “Class Period”)....
Oct 26, 2022 10:40 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT
NEW YORK, Oct. 26, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Oct 26, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Latch, Azure, Abbott, and TuSimple and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Latch, Inc. (NASDAQ: LTCH), Azure Power Global Limited (NYSE: AZRE), Abbott...
Oct 26, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Abbott Laboratories of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 31, 2022 - (NYSE: ABT)
NEW YORK, Oct. 26, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Abbott Laboratories.
Oct 25, 2022 10:56 pm ET
ABBOTT LABORATORIES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they purchased the...
Oct 25, 2022 04:17 pm ET
ABT FINAL DEADLINE MONDAY: GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Abbott Laboratories Investors to Secure Counsel Before Important October 31 Deadline in Securities Class Action – ABT
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the “Class Period”), of the important October 31, 2022...
Oct 25, 2022 05:45 am ET
ABT ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 31, 2022 in the Class Action Filed on Behalf of Abbott Laboratories Shareholders
NEW YORK, Oct. 25, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Abbott Laboratories (NYSE: ABT) alleging that the Company violated federal securities laws.
Oct 25, 2022 01:45 am ET
ABBOTT LABORATORIES (NYSE: ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Ab
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Oct 24, 2022 03:04 pm ET
Moore Kuehn Encourages Investors of Abbott Laboratories to Contact Law Firm
Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against: Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT) ***Please contact [email protected] Abbott is a...
Oct 24, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Abbott Investors of a Lead Plaintiff Deadline of October 31, 2022
NEW YORK, Oct. 24, 2022 /PRNewswire/ -- Attention Abbott Laboratories ("Abbott") (NYSE: ABT) shareholders:
Oct 23, 2022 06:22 am ET
Oct 22, 2022 04:28 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT
, October 22, 2022 (GLBENEWSWIRE) Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT). Such investors are advised to contact Robert S. Willoughby at [email protected] or...
Oct 21, 2022 10:50 pm ET
ABBOTT LABORATORIES SHAREHOLDER ALERT: CLAIMSFILER Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT
NEW ORLEANS, Oct. 21, 2022 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they purchased the Company's shares between February 19, 2021 to June 8, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of Illinois.
Oct 21, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Humanigen, Latch, Azure, and Abbott and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Humanigen, Inc. (NASDAQ: HGEN), Latch, Inc. (NASDAQ: LTCH), Azure Power Global...
Oct 21, 2022 05:45 am ET
ABT SHAREHOLDER ALERT: Jakubowitz Law Reminds Abbott Shareholders of a Lead Plaintiff Deadline of October 31, 2022
NEW YORK, Oct. 21, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Abbott Laboratories (NYSE: ABT).
Oct 20, 2022 04:11 pm ET
ABT FINAL DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Abbott Laboratories Investors with Losses in Excess of $100K to Secure Counsel Before Important October 31 Deadline in Securities
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the “Class Period”), of the important October 31, 2022...
Oct 20, 2022 05:45 am ET
ABT LAWSUIT ALERT: Levi & Korsinsky Notifies Abbott Laboratories Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Oct. 20, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT) of a class action securities lawsuit.
Oct 19, 2022 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Abbott Laboratories - ABT
CEDARHURST, N.Y., Oct. 19, 2022 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Abbott Laboratories (NYSE: ABT), if they purchased the Company's shares between February 19, 2021 to June 8, 2022, inclusive (the "Class Period"). Shareholders have until October 31, 2022 to file lead plaintiff applications in the securities class action lawsuit.
Oct 19, 2022 11:42 am ET
AZRE, ABT & LTCH Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Oct 19, 2022 08:00 am ET
Abbott Investors: Please contact the Portnoy Law Firm to recover your losses; Last day to actively participate in the case; October 31, 2022
The Portnoy Law Firm advises Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT) investors that a class action has been filed on behalf of investors. Abbott investors that lost money on their investment are encouraged to contact Lesley...
Oct 19, 2022 07:30 am ET
Abbott Reports Third-Quarter 2022 Results and Raises Full-Year EPS Guidance
Worldwide sales of $10.4 billion in the third quarterRaises full-year earnings-per-share guidanceContinues to strengthen portfolio with new product approvals and launchesABBOTT PARK, Ill., Oct. 19, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2022.
Oct 19, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Abbott Laboratories of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 31, 2022 - (NYSE: ABT)
NEW YORK, Oct. 19, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Abbott Laboratories.
Oct 19, 2022 12:54 am ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT
NEW YORK, Oct. 19, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Oct 18, 2022 10:49 pm ET
ABBOTT LABORATORIES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsui
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against...
Oct 18, 2022 01:45 am ET
ABBOTT LABORATORIES (NYSE: ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Ab
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Oct 17, 2022 11:58 pm ET
MOORE KUEHN ENCOURAGES INVESTORS OF ABBOTT LABORATORIES TO CONTACT LAW FIRM
NEW YORK, Oct. 17, 2022 /PRNewswire/ -- Moore Kuehn, PLLC, a securities and shareholder law firm located on Wall Street, is investigating potential claims against:
Oct 16, 2022 11:18 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Abbott, TuSimple, Kohl’s, and Bed Bath & Beyond and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Abbott Laboratories (NYSE: ABT), TuSimple Holdings, Inc. (NASDAQ: TSP), Kohl’s...
Oct 16, 2022 11:00 am ET
ROSEN, A TOP RANKED FIRM, Encourages Abbott Laboratories Investors to Secure Counsel Before Important October 31 Deadline in Securities Class Action – ABT
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the “Class Period”), of the important October 31, 2022...
Oct 15, 2022 06:18 am ET
Oct 14, 2022 10:50 pm ET
ABBOTT LABORATORIES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds Investors with Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsui
NEW ORLEANS, Oct. 14, 2022 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they purchased the Company's shares between February 19, 2021 to June 8, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of Illinois.
Oct 14, 2022 09:04 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT
Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Oct 14, 2022 05:45 am ET
ABT SHAREHOLDER ALERT: Jakubowitz Law Reminds Abbott Shareholders of a Lead Plaintiff Deadline of October 31, 2022
NEW YORK, Oct. 14, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Abbott Laboratories (NYSE: ABT).
Oct 13, 2022 05:45 am ET
ABT LAWSUIT ALERT: Levi & Korsinsky Notifies Abbott Laboratories Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Oct. 13, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT) of a class action securities lawsuit.
Oct 12, 2022 10:53 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Abbott Laboratories - ABT
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Abbott Laboratories (NYSE: ABT), if they purchased the Company’s shares between February 19, 2021 to June 8, 2022, inclusive (the “Class Period”)....
Oct 12, 2022 08:39 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Abbott, TuSimple, Kohl’s, and Bed Bath & Beyond and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Abbott Laboratories (NYSE: ABT), TuSimple Holdings, Inc. (NASDAQ: TSP), Kohl’s...
Oct 12, 2022 07:56 pm ET
ABBOTT LABORATORIES INVESTIGATION REMINDER ALERT: Scott+Scott Attorneys at Law LLP Continues to Investigate Abbott Laboratories’ Directors and Officers for Breach of Fiduciary Duties – ABT
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), a national securities and consumer rights litigation firm, reminds investors that it continues to investigate whether certain directors and officers of Abbott Laboratories (“Abbott”) (NYSE: ABT)...
Oct 12, 2022 09:42 am ET
Abbott and The Home Edit Redesign the Medicine Cabinet to Help People Prepare for the Upcoming Virus Season
Flu and virus seasons have become more unpredictable with the addition of COVID-19The Home Edit and Abbott aim to bring peace of mind to families when it comes to their health by organizing medicine cabinets in time for the cold and flu seasonRapid at-home tests remain an important health tool for COVID-19, providing fast and reliable resultsABBOTT PARK, Ill., Oct. 12, 2022 /PRNewswire/ -- As we enter cold and flu season amid continuing COVID-19 cases, Abbott (NYSE: ABT), makers of BinaxNOW™ COVID-19 Antigen Self Test, and The Home Edit, the world's number one organizational company and a gl
Oct 12, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Abbott Laboratories of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 31, 2022 - (NYSE: ABT)
NEW YORK, Oct. 12, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Abbott Laboratories.
Oct 11, 2022 10:53 pm ET
ABBOTT LABORATORIES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they purchased the...
Oct 11, 2022 09:10 am ET
Meet Abbott's Working Parents of the Year
NORTHAMPTON, MA / ACCESSWIRE / October 11, 2022 / Abbott exists to help people around the world live their fullest lives - and we know that for many of our employees that includes being a parent.
Oct 11, 2022 01:45 am ET
ABBOTT LABORATORIES (NYSE: ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Ab
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Oct 10, 2022 06:59 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT
NEW YORK, Oct. 10, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Oct 10, 2022 04:07 pm ET
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action – ABT
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the “Class Period”), of the important October 31, 2022...
Oct 10, 2022 09:10 am ET
Nurturing Healthier Living in a "Care Desert"
NORTHAMPTON, MA / ACCESSWIRE / October 10, 2022 / Abbott:
Oct 07, 2022 10:50 pm ET
ABBOTT LABORATORIES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT
NEW ORLEANS, Oct. 7, 2022 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they purchased the Company's shares between February 19, 2021 to June 8, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of Illinois.
Oct 07, 2022 10:10 pm ET
ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT
NEW YORK, Oct. 7, 2022 /PRNewswire/ --
Oct 07, 2022 05:45 am ET
ABT SHAREHOLDER ALERT: Jakubowitz Law Reminds Abbott Shareholders of a Lead Plaintiff Deadline of October 31, 2022
NEW YORK, Oct. 7, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Abbott Laboratories (NYSE: ABT).
Oct 06, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Azure, Abbott, TuSimple, and Kohl’s and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Azure Power Global Limited (NYSE: AZRE), Abbott Laboratories (NYSE: ABT),...
Oct 06, 2022 05:18 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT
Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Oct 06, 2022 09:00 am ET
New Study Published in The New England Journal of Medicine Demonstrates Abbott's FreeStyle Libre® 2 System Has Positive Impacts on Glucose Levels and Quality of Life
Randomized clinical trial of Abbott's FreeStyle Libre 2 system compared to self-monitoring of blood glucose (SMBG) shows FreeStyle Libre 2 leads to significant reductions in glycated hemoglobin (HbA1c) levels at 24 weeks in people with Type 1 diabetes and sub-optimal glycemic control1People using the FreeStyle Libre technology had average HbA1c levels a significant 0.5% lower than those using SMBG at the end of the study period1The FreeStyle Libre 2 system use was also linked to improvements in overall satisfaction and reduced burden associated with glucose monitoring1ABBOTT PARK, Ill., Oct.
Oct 06, 2022 05:45 am ET
ABT LAWSUIT ALERT: Levi & Korsinsky Notifies Abbott Laboratories Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Oct. 6, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT) of a class action securities lawsuit.
Oct 05, 2022 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Abbott Laboratories - ABT
CEDARHURST, N.Y., Oct. 5, 2022 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Abbott Laboratories (NYSE: ABT), if they purchased the Company's shares between February 19, 2021 to June 8, 2022, inclusive (the "Class Period"). Shareholders have until October 31, 2022 to file lead plaintiff applications in the securities class action lawsuit.
Oct 05, 2022 04:58 pm ET
ABT DEADLINE ALERT: Hagens Berman, National Trial Attorneys, Encourages Abbott Laboratories (ABT) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Pending
Hagens Berman urges Abbott Laboratories (NYSE: ABT) investors who suffered significant losses to submit your losses now. Class Period: Feb. 19, 2021 – June 8, 2022Lead Plaintiff Deadline: Oct. 31, 2022Visit:...
Oct 04, 2022 10:50 pm ET
ABBOTT LABORATORIES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsui
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against...
Oct 04, 2022 05:45 am ET
ABT ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 31, 2022 in the Class Action Filed on Behalf of Abbott Laboratories Shareholders
NEW YORK, Oct. 4, 2022 /PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Abbott Laboratories (NYSE: ABT) alleging that the Company violated federal securities laws.
Oct 04, 2022 01:45 am ET
ABBOTT LABORATORIES (NYSE: ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Ab
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Oct 03, 2022 04:15 pm ET
ABT SHAREHOLDER ALERT: ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action – ABT
WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abbott Laboratories (NYSE: ABT) between February 19, 2021 and June 8, 2022, both dates inclusive (the “Class Period”), of the important October 31,...
Oct 03, 2022 12:10 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT
NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.
Oct 03, 2022 05:45 am ET
CLASS ACTION ALERT: The Law Offices of Vincent Wong Remind Abbott Investors of a Lead Plaintiff Deadline of October 31, 2022
NEW YORK, Oct. 3, 2022 /PRNewswire/ -- Attention Abbott Laboratories ("Abbott") (NYSE: ABT) shareholders:
Oct 02, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Azure, Abbott, TuSimple, and Kohl’s and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Azure Power Global Limited (NYSE: AZRE), Abbott Laboratories (NYSE: ABT),...
Sep 30, 2022 10:50 pm ET
ABBOTT LABORATORIES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsui
NEW ORLEANS, Sept. 30, 2022 /PRNewswire/ -- Kahn Swick & Foti, LLC ("KSF") and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they purchased the Company's shares between February 19, 2021 to June 8, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of Illinois.
Sep 30, 2022 11:39 am ET
AZRE, ABT & LTCH Class Action Deadlines: Bronstein, Gewirtz & Grossman, LLC, A Top Class Action Firm, Reminds Investors of Last Day to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Sep 30, 2022 05:45 am ET
ABT SHAREHOLDER ALERT: Jakubowitz Law Reminds Abbott Shareholders of a Lead Plaintiff Deadline of October 31, 2022
NEW YORK, Sept. 30, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Abbott Laboratories (NYSE: ABT).
Sep 29, 2022 05:45 am ET
ABT LAWSUIT ALERT: Levi & Korsinsky Notifies Abbott Laboratories Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK, Sept. 29, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT) of a class action securities lawsuit.
Sep 28, 2022 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Abbott Laboratories - ABT
The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Abbott Laboratories (NYSE: ABT), if they purchased the Company’s shares between February 19, 2021 to June 8, 2022, inclusive (the “Class Period”)....
Sep 28, 2022 03:15 pm ET
ROSEN, A LONGSTANDING LAW FIRM, Encourages Abbott Laboratories Investors to Secure Counsel Before Important Deadline in Securities Class Action - ABT
NEW YORK, Sept. 28, 2022 /PRNewswire/ --
Sep 28, 2022 09:00 am ET
Abbott Hosts Conference Call for Third-Quarter Earnings
ABBOTT PARK, Ill., Sept. 28, 2022 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its third-quarter 2022 financial results on Wednesday, Oct. 19, 2022, before the market opens.
Sep 28, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Abbott Laboratories of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 31, 2022 - (NYSE: ABT)
NEW YORK, Sept. 28, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Abbott Laboratories.
Sep 27, 2022 10:52 pm ET
ABBOTT LABORATORIES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT
ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they purchased the...
Sep 27, 2022 04:12 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abbott Laboratories - ABT
Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Sep 27, 2022 02:01 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Abbott Laboratories (ABT) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Class Action Pending
Hagens Berman urges Abbott Laboratories (NYSE: ABT) investors who suffered significant losses to submit your losses now. Class Period: Feb. 19, 2021 – June 8, 2022Lead Plaintiff Deadline: Oct. 31, 2022Visit:...
Sep 27, 2022 01:45 am ET
ABBOTT LABORATORIES (NYSE: ABT) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Ab
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to file a lead plaintiff motion in a securities class action lawsuit that has been filed on behalf of investors who purchased or acquired the...
Sep 26, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Humanigen, Latch, Azure, and Abbott and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Humanigen, Inc. (NASDAQ: HGEN), Latch, Inc. (NASDAQ: LTCH), Azure Power Global...
Sep 26, 2022 11:46 am ET
AZRE, ABT & LTCH Class Action Reminders: Bronstein, Gewirtz & Grossman, LLC, A Successful Firm, Reminds Investors to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Sep 23, 2022 10:50 pm ET
ABBOTT LABORATORIES SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Abbott Laboratories - ABT
NEW ORLEANS, Sept. 23, 2022 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against Abbott Laboratories (NYSE: ABT), if they purchased the Company's shares between February 19, 2021 to June 8, 2022, inclusive (the "Class Period"). This action is pending in the United States District Court for the Northern District of Illinois.
Sep 23, 2022 05:45 am ET
ABT SHAREHOLDER ALERT: Jakubowitz Law Reminds Abbott Shareholders of a Lead Plaintiff Deadline of October 31, 2022
NEW YORK, Sept. 23, 2022 /PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Abbott Laboratories (NYSE: ABT).
Sep 22, 2022 01:07 pm ET
HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Encourages Abbott Laboratories (ABT) Investors with Significant Losses to Contact Firm’s Attorneys, Deadline Approaching in Securities Fraud Class Action
Hagens Berman urges Abbott Laboratories (NYSE: ABT) investors who suffered significant losses to submit your losses now. Class Period: Feb. 19, 2021 – June 8, 2022Lead Plaintiff Deadline: Oct. 31, 2022Visit:...
Sep 22, 2022 05:45 am ET
ABT LAWSUIT ALERT: Levi & Korsinsky Notifies Abbott Laboratories Investors of a Class Action Lawsuit and Upcoming Deadline
NEW YORK , Sept. 22, 2022 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Abbott Laboratories ("Abbott" or the "Company") (NYSE: ABT) of a class action securities lawsuit.
Sep 21, 2022 10:50 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Action on Behalf of Shareholders of Abbott Laboratories - ABT
CEDARHURST, N.Y., Sept. 21, 2022 /PRNewswire/ -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of Abbott Laboratories (NYSE: ABT), if they purchased the Company's shares between February 19, 2021 to June 8, 2022, inclusive (the "Class Period"). Shareholders have until October 31, 2022 to file lead plaintiff applications in the securities class action lawsuit.
Sep 21, 2022 09:00 pm ET
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Abbott, TuSimple, Kohl’s, and Sema4 and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Abbott Laboratories (NYSE: ABT), TuSimple Holdings, Inc. (NASDAQ: TSP), Kohl’s...
Sep 21, 2022 04:44 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Abbott Laboratories - ABT
Pomerantz LLP is investigating claims on behalf of investors of Abbott Laboratories (“Abbott” or the “Company”) (NYSE: ABT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980. The...
Sep 21, 2022 05:45 am ET
SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Abbott Laboratories of a Class Action Lawsuit and a Lead Plaintiff Deadline of October 31, 2022 - (NYSE: ABT)
NEW YORK, Sept. 21, 2022 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Abbott Laboratories.
Sep 20, 2022 10:57 pm ET
ABBOTT LABORATORIES SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsui
Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until October 31, 2022 to file lead plaintiff applications in a securities class action lawsuit against...
Sep 20, 2022 11:36 am ET
AZRE, ABT & LTCH Class Action Deadlines: Bronstein, Gewirtz & Grossman, LLC, A Top Class Action Firm, Reminds Investors of Last Day to Actively Participate
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Disclaimer :: Use of this site is subject to, and your continued use
constitutes your express agreement to be bound by, our Legal and Terms of Use. Any commercial use of this site is
strictly prohibited. Insidertracking.com is operated by INK Research Corp (INK). INK provides general information.
INK has made all reasonable efforts to ensure that all information provided is accurate at the time of inclusion;
however, there may be errors. INK makes no guarantee of accuracy or completeness. All information and opinion
expressed herein is subject to change without notice. Insider information is based on filings made either on EDGAR®
or on the System for Electronic Disclosure for Insiders (SEDI®). Data is provided “as is” and by using this site
you acknowledge that the information which comprises the data is filed by or on behalf of the SEDI filers or other
parties legally required or permitted to do so. Filings may at any time contain errors and by using this site you
acknowledge this fact. INK is not an investment advisory service, a financial planner, an investment advisor nor a
securities advisor. INK does not purport to tell people, or suggest to people, what they should buy or sell for
themselves. Opinions and recommendations contained herein should not be construed as investment advice. Do not
assume that any recommendations, insights, charts, theories, or philosophies will ensure profitable investment.
Users should always consult with and obtain advice from their professional licensed financial advisor, including
their tax advisor, to determine the suitability of any investment. INK recommends that anyone making an investment
or trading securities do so with caution. Users should perform full due diligence and investigate any security
fully before making an investment or before the execution of a security trade based upon information learned
through INK. Investors should obtain annual reports and other company information to complete their own due
diligence in any investment. Neither INK nor anyone affiliated with INK is responsible for any investment decision
made. INK employees may have an ownership or investment interest in any stock mentioned in this service or on this
website. On this site, there may be third party content, content from authors or links to third-party sites or
pages, the contents of which are not verified, maintained, controlled or supervised by INK. INK is not responsible
for and assumes no liability for the accuracy, completeness or timeliness of any third party content or authored
content provided herein or the information or contents of any linked sites or pages. The inclusion of any authored
content or link by us does not imply that INK recommends, approves or endorses the authored content or linked site
or pages. INK Edge® and INK Research® are registered trade-marks owned by INK Research Corp. SEDI®
is a registered trade-mark owned by the Alberta Securities Commission. Copyright © 2024 INK Research Corp. All rights reserved.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.
Please make the indicated changes including the new text: US quotes snapshot data provided by IEX. Additional price data and company information powered by Twelve Data.